Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Artelo Biosciences (ARTL – Research Report), Iterum Therapeutics (ITRM – Research Report) and TScan Therapeutics (TCRX – Research Report).

Artelo Biosciences (ARTL)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Artelo Biosciences today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.71, close to its 52-week low of $1.39.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 13.7% and a 30.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Blue Water Vaccines, Inc., Finch Therapeutics Group, and Citius Pharmaceuticals.

Currently, the analyst consensus on Artelo Biosciences is a Strong Buy with an average price target of $18.33, representing a 959.5% upside. In a report issued on May 12, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $40.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics today. The company’s shares closed last Wednesday at $1.12, close to its 52-week low of $0.60.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.0% and a 44.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Paratek Pharmaceuticals, and Enanta Pharmaceuticals.

Iterum Therapeutics has an analyst consensus of Hold.

TScan Therapeutics (TCRX)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on TScan Therapeutics, with a price target of $15.00. The company’s shares closed last Wednesday at $3.57.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 3.7% and a 42.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

TScan Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARTL:

• Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
• Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
• Artelo Biosciences initiates Phase 2a portion of CAReS trial of ART27.13
• Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
• Artelo Biosciences expects cash to fund operations into 2H24